Primary effusion lymphoma: successful treatment with highly active antiretroviral therapy and rituximab.
Lim
Soon Thye
ST
Rubin
Nancy
N
Said
Jonathan
J
Levine
Alexandra M
AM
D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D019288:Herpesvirus 8, Human / Q000302:isolation & purification; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D016483:Lymphoma, AIDS-Related / Q000175:diagnosis / Q000188:drug therapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000175:diagnosis / Q000188:drug therapy; D010490:Pericardial Effusion / Q000473:pathology; D016066:Pleural Effusion, Malignant / Q000175:diagnosis / Q000188:drug therapy* / Q000821:virology; D012074:Remission Induction; D000069283:Rituximab
D044966:Anti-Retroviral Agents; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab